Category Archives: Issue 6 December 17

Datesand at LASA

img_9434It was a frosty winter’s morning when we, once again, set off to set up the Datesand stand for another LASA Winter Meeting in Birmingham.  At the now-familiar venue we were met by the super helpful Stuart Lamming and his team who helped me with my first issue of the week – that I’d booked myself in incorrectly!!  After a small panic about who I’d booked where, I was relieved to discover that Jonathon and Ryan’s bookings were correct – phew!

Ryan and I then set about opening our pallets and starting to assemble the Datesand stand.  A few grumbles later about height and the pallets were unpacked, the carpet was down and the frame was up.  After a quick snack break (the fish finger sandwich looked great!) we were ready to go again and by tea time the stand was looking fab.

Feeling pretty accomplished we had a relaxed evening in the bar with a few customers and trade colleagues and readied ourselves for the start of the main meeting the following day…

to be continued…

Datesand Crossing Continents – SALAS

We’re delighted to be represented now in Singapore and Malaysia by our friends at iDNA Biotechnology. iDNA are a very well established company based in Singapore, with a  strong business and distribution network in South East Asia.

Our photo shows the iDNA stand at the recent SALAS (Singapore Association for Laboratory Animal Science) exhibition in Singapore. We were very excited to see our products and banner stands on display at this important national meeting.



The Stars come out at night for UNICEF

unicef-2As a life-long Manchester United Fan, Jonathon was really delighted to receive an invitation for him and his wife Claire to join players and supporters at the annual  MUFC UNICEF charity dinner held this month. This year’s dinner celebrated 18 years of the partnership between Manchester United and UNICEF, the world’s leading children’s organisation.

Hosted by Mark Chapman and Rachel Riley and attended by all of the first team squad and staff, it was a star-studded occasion – topped off with a solo performance by Stormzy!

Jonathon and Claire report that the players were extremely friendly and open to talk and take selfies. Jonathon also mentioned that the only slightly morose looking figure present was, true to form, a certain Mr Mourhino!!

The annual event has helped to raise over £4 million for Unicef over the years. This year’s extravaganza netted over £200,000 for the organisation aimed particularly at its vital work in Thailand supporting education programmes for children with little or no access to schooling.

It was a great evening enjoyed by all – hopefully we’ll be invited again next year!

unicef-3 unicef-1


AALAS Bulletin from our social affairs correspondent, Ryan Hill

img_9138AALAS really does bring people together from across the globe for science, business and, of course, those highly enjoyable social events.

As the 2017 meeting drew to its close, it was only fitting for us Brits to follow tradition and conclude another fantastic conference with the now legendary Brits Night! Painstakingly organised by our own Nicky Windows, this year’s event saw the coming together of 43 British AALAS delegates.

The  evening was held  at an old school American bar named Buffalo Billiards. Pool and billiard tables were available to enjoy whilst socialising and catching up with fellow colleagues. The venue itself as well as the food and drinks were kindly sponsored by Agenda, Allentown, Datesand, Fuel 3D,  IPS, Rees Scientific, Sychem and Tecniplast.img_9152

Our sincere thanks to all the sponsors. With your support, everyone was able to enjoy yet another really successful Brits night.

The event ended at approximately 9pm. For many of us though, the party continued as we moved on to what had become our regular venue, The Blind Pig. There was music, dancing, lots of chat as well as more memories made and friendships forged.

NHS must drive forward life sciences

NHS must drive forward life sciences strategy, says Lords’ leader

November 28, 2017

lord-patelThe success of the government’s life sciences strategy hinges on the NHS using novel medicines and therapies, according to Lord Patel, the peer leading an inquiry into the sector.

Lord Patel is chair of the Lords Science and Technology Select Committee, which today takes evidence from big US pharma companies, including MSD, which has just announced a major investment in an R&D centre in London.

Representatives of two other big US pharma companies, Pfizer and Johnson & Johnson’s Janssen unit, will also give evidence this morning.

Originally trained as an obstetrician, Lord Patel has a strong background in biomedical sciences and is leading the committee’s inquiry into the life sciences strategy, after the sector was one of four that have been given special deals to boost growth.

The other three sectors are construction, automotive and Artificial Intelligence. The life sciences sector deal has been agreed, but more detail will be announced next week.

But Lord Patel is the latest to stress the importance of the NHS, the single largest consumer of health products in the country.

Unfortunately, the NHS has a reputation for slow adoption of the latest drugs and therapies, and the argument is that this must change if the pharma and life sciences sector is to achieve its true potential, as well as ensuring patients get the best possible treatments and outcomes.

He told pharmaphorum in an interview ahead of today’s evidence session that MSD’s announcement is “very important for the UK” and the life sciences sector deal.

The government is already trying to encourage use of novel drugs and therapies, by creating an Accelerated Access Pathway that will select a handful of products, hasten their clinical development, and encourage their use in the NHS.

But this is set against a backdrop of a continued squeeze on funding, and an annual struggle to meet waiting times targets in A&E and cancer each winter because services cannot meet demand.

Although the chancellor Philip Hammond in his Autumn Budget pledged an extra £2.8 billion in funding to relieve pressures until 2020, critics have said this still falls short

“What this demonstrates is the confidence in life sciences and biomedical life sciences. It is true that biomedical sciences are quite strong. We are well regarded in our biomedical sciences and companies large and small will be interested if we can develop this.”

“What is important is how this will be driven by the NHS. It will only happen with the NHS,” said Lord Patel.

Lord Patel said that a body with oversight of the life sciences strategy will be a key part of the sector deal, and will need to be influential to steer the plan to success.

“There will be a creative council that will report to the government – it is important to see how high a level it is and how much authority it has.”

Labour has criticised the sector deals, saying that the government should be focusing on improving productivity, and pay and conditions, in industries such as hospitality.

In response to this, the crossbench peer said: “What the plan is about is investing over 10 years in life sciences. That does not mean we are not interested in other sectors, or other services.”